The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Michael McIntyre recently showcased his weight loss transformation in London, attributing it to the use of Mounjaro. He openly discussed his journey, including initial reluctance and subsequent positive results. He also commented on others using similar methods.
Pfizer has successfully acquired Metsera, a company specializing in obesity drug development, for $10 billion, prevailing over Novo Nordisk in a competitive bidding process. This acquisition marks Pfizer's entry into the expanding obesity drug market. Metsera's treatments are still several years from regulatory approval.
The global market for oral proteins and peptides is experiencing rapid expansion, with projections estimating a value of US$ 47.2 billion by 2035. This growth, driven by increasing demand for peptide-based therapeutics and advancements in delivery technologies, signifies a dynamic shift in the pharmaceutical and nutraceutical landscape.
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
A recent study presented at ObesityWeek suggests that setmelanotide, when used alongside GLP-1 therapy, may lead to a substantial reduction in BMI for individuals with acquired hypothalamic obesity. The research indicates that restoring melanocortin-4 receptor pathway signaling could improve response to other anti-obesity treatments.
AstraZeneca has completed the acquisition of SixPeaks Bio, marking a significant step in developing advanced obesity treatments. The deal involves an initial payment of $170 million, with potential milestone payments to follow, focusing on therapies that preserve muscle mass during weight loss.
Eli Lilly is progressing its experimental amylin obesity drug, eloralintide, into late-stage clinical trials following successful phase 2 study outcomes. The mid-stage study demonstrated significant weight loss in participants receiving the highest dose of the drug.
The Phase III OASIS 4 trial revealed that Novo Nordisk's oral Wegovy (semaglutide) reduced cardiovascular risk factors in individuals with obesity. The study supports the drug's approval, showing improvements in C-reactive protein and serum triglycerides. Blood sugar control also improved among patients.
Eli Lilly is set to begin late-stage trials for its investigational amylin obesity drug following promising mid-stage study results. The trial showed the highest dose of the weekly injection, eloralintide, resulted in an average weight loss of 20.1% in obese or overweight patients over 48 weeks.
